RARE – ultragenyx pharmaceutical inc. (US:NASDAQ)
Stock Stats
News
2/6
10:16 pm
rare
Neutral
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
2/6
12:10 pm
rare
Low
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
2/6
11:41 am
rare
Low
Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE)
2/6
08:49 am
rare
Medium
RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
2/6
07:40 am
rare
Medium
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE
11/4/2025
04:05 pm
rare
-1.8%
MISS
8/5/2025
04:07 pm
rare
-4.9%
BEAT
5/6/2025
04:01 pm
rare
-4.7%
MISS
2/13/2025
04:01 pm
rare
-2.4%
MISS
2/3
08:44 am
Reiterates
Buy
Buy
HC Wainwright
Low
1.2%
1/5
08:02 am
Maintains
Buy
Buy
Guggenheim
Low
-2.4%
1/5
08:02 am
Maintains
Buy
Buy
Guggenheim
Low
-2.4%
12/30
12:55 pm
Maintains
Outperform
Outperform
Leerink Partners
Low
2.3%
12/30
12:53 pm
Maintains
Outperform
Outperform
Baird
Low
2.7%
2/5
01:41 pm
rare
Low
Form SCHEDULE 13G/A Ultragenyx Pharmaceutica Filed by: FMR LLC
2/3
12:01 pm
rare
Low
Form 4 Ultragenyx Pharmaceutica For: Feb 02 Filed by: Horn Howard
2/3
08:15 am
rare
Low
Form 8-K Ultragenyx Pharmaceutica For: Feb 03
2/2
04:09 pm
rare
Low
Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard
1/30
08:45 am
rare
Low
Form 8-K Ultragenyx Pharmaceutica For: Jan 30
Show more
Top News Gainers
1/9 Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 23.4%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
Top News Decliners
3/16 GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome -21.2%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3